Compounds in this category
BPC-157 is the most-searched compound in this category. The 15-amino-acid synthetic peptide has been tested in rat injury models continuously since 1991, mostly by Predrag Sikiric's group in Zagreb. Published rat data covers gastric ulcer healing, colitis lesion repair, transected tendon and ligament regeneration, muscle crush injury recovery, and corneal wound healing. Effect sizes versus saline controls are reported as large in these models. Zero randomized controlled human trials have been published for any tissue-healing endpoint. The compound is sold as a research chemical under Research Use Only (RUO) labeling in the US and EU. WADA-prohibited.
TB-500 is marketed as a synthetic equivalent of thymosin beta-4, the actin-binding protein involved in cell migration and wound repair. Pharmaceutical-grade thymosin beta-4 has progressed through Phase 2 trials for dry eye disease, venous stasis ulcers, and dermal wound repair. The grey-market "TB-500" sold to consumers is not the same regulated drug substance. Athletes should treat the compound as WADA-prohibited.
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) has the strongest dermal evidence in the tissue healing category. The tripeptide was identified by Loren Pickart in 1973. Published topical clinical trials demonstrate measurable improvements in skin density, wound closure rate, and elasticity. The compound is regulated as a cosmetic in topical applications and is not approved as an injectable drug. Mechanism involves copper-dependent enzyme activation, decorin upregulation, and modulation of dermal repair pathways.
KPV is a C-terminal tripeptide of alpha-MSH studied preclinically for inflammatory tissue repair. Mouse colitis models and topical wound models report reduced inflammation and faster healing. Human trial data has not been published. The compound is sold as a research chemical.
Pentadeca arginate is positioned as a stabilized analog with a similar use case to BPC-157. Peer-reviewed clinical evidence is currently limited. The compound page treats marketing claims as hypothesis.
Thymosin beta-4 (the pharmaceutical-grade compound, distinct from research-chemical TB-500) reached Phase 2 development for multiple wound-healing indications. The clinical program has been intermittent. Some trials reported promising early outcomes. None has produced a Phase 3 approval. The full clinical-trial registry on ClinicalTrials.gov reflects this trajectory.
Cross-category overlap
Many of these compounds appear in multiple effect categories on PeptScope. BPC-157 sits in tissue healing, tendon repair, recovery, and gut health. TB-500 appears in tissue healing, tendon repair, and recovery. GHK-Cu spans skin anti-aging, tissue healing, and recovery. The overlap reflects shared mechanism proposals (angiogenesis, growth factor modulation, extracellular matrix remodeling) rather than independent clinical evidence for each indication.
Readers screening this category should treat the evidence tier as compound-specific, not category-wide. A peptide with strong topical dermal-healing data does not automatically translate to systemic tissue repair. A peptide with strong rat-tendon data does not automatically have human wound-healing efficacy.
Where the evidence is genuinely solid
The tissue-healing peptides with the strongest evidence are not the ones online discussion focuses on. Topical GHK-Cu has multiple human dermal trials. Pharmaceutical thymosin beta-4 reached Phase 2 in defined wound populations. Becaplermin (recombinant PDGF, sold as Regranex) is FDA-approved for diabetic foot ulcers and is technically a peptide-class drug, though it falls outside the typical research-peptide market.
The evidence picture for the high-volume research peptides is dominated by preclinical animal work, with named research groups producing consistent in-house data and limited independent replication. Sikiric's BPC-157 program is the clearest example: more than 100 rat studies, zero published human RCTs.
Regulatory and doping notes
BPC-157, TB-500, KPV, and pentadeca arginate are not approved for human use by the FDA or EMA. They are sold under Research Use Only labeling. BPC-157 and TB-500 are WADA-prohibited. GHK-Cu cosmetic products are regulated as cosmetics, not as drugs. Where dosing is reported on each compound page, it is from the cited literature. PeptScope does not frame dosing as personal advice and does not link to vendors.